BVS · Bioventus Inc.
$14.38
+0.05 (+0.35%)
At close · Aug 21
Market Cap
$1.21B
Shares
84.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.38
Open$14.33
Day$14.20–14.41
52W close$6.51–15.26
Avg vol 30d762K
Short int2.5M · 3.0% float · 3.9d
Short vol57%
Last earningsAug 5, 2026
DataFeb 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+21%
above
RSI (14)
62
neutral
MACD trend
Negative
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
+64%
trailing
YTD return
+93%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.02% of float · ▼ -7.1% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−1%
Y/Y
Gross margin
68%
expanding
EPS growth
+159%
Y/Y
Free cash flow
$72.1M
Valuation
P/E 18.7
below peers
Balance sheet
$242.7M
net debt
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Cash from Operations
· twelve months ending December 31, 2026
Initiated
$84M – $89M
Adjusted EPS
· twelve months ending December 31, 2026
Non-GAAP
Initiated
$0.75 – $0.79
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Non-GAAP EPS
· twelve months ending December 31, 2025
$0.64 – $0.68
Guided vs delivered
· last 2 settled
Net sales
2024
guided $535M – $550M
$573.28M
Beat +5.7%
2023 revenue
2023
guided $498M – $505M
$512.35M
Beat +2.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+21%
Bullish
RSI (14)
62
Neutral
MACD trend
Negative
Bearish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.02% of float · ▼ -7.1% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7
Now $14 · 90%
Range high $15
vs 200-day avg +53%
vs 50-day avg +21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $35.3M | Q2 2026 | +4.6% |
|
|
|||
| Cash from operations | $19.9M | Q2 2026 | — |
|
|
|||
| Non-GAAP earnings per diluted share non-GAAP | $0.22 | Q2 2026 | — |
|
|
|||
| Adjusted EPS non-GAAP | $0.15 | Three Months Ended March 28, 2026 | +87.5% |
|
|
|||
| Non-GAAP Gross Margin non-GAAP | 76.4% | Three Months Ended March 28, 2026 | +1.5% |
|
|
|||
| Non-GAAP Operating Margin non-GAAP | 15.4% | Three Months Ended March 28, 2026 | +7.7% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BVS
this stock
Bioventus Inc.
|
$1.21B | +93.3% | -0.9% | 18.7 | 3.0% |
|
ABT
Abbott Laboratories
|
$203.17B | -6.9% | +5.7% | 32.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.37B | -6.3% | +11.2% | 34.1 | 2.2% |
|
MDT
Medtronic plc
|
$119.49B | -2.8% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.00B | -47.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BVS | +0.8% | +21.9% | +64.0% | +9.2% | +93.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.2% | +18.2% | +52.4% | +6.7% | +81.0% |
Key facts
CIK
1665988
CUSIP
09075A108
13F (30d)
144 filings
142 filers
Visit website
Investor relations